Biodexa Pharmaceuticals Plc (BDRX) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.02
↓-97% vs avg
5yr avg: 0.60
30Y Low0.0·High1.5
ROE
↑
-63.4%
↓+38% vs avg
5yr avg: -101.6%
30Y Low-181%·High-13%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BDRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Biodexa Pharmaceuticals Plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $622672 | $13M | $100500 | $394000 | $999999 | $999999 | — | — | — | — |
| Enterprise Value | $-10377643 | $-7835435 | $12M | $-5406500 | $-1818000 | $-8291001 | $-6286001 | — | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 0.26 | 0.56 | 1.73 | 2.92 | — | — | — | — |
| P/B Ratio | 0.02 | 0.05 | 1.51 | 0.02 | 0.39 | 1.00 | 1.00 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BDRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -14.19 | -2.60 | -14.34 | -18.33 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BDRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -63.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -967.5% | -631.2% | -705.2% | -1669.1% | -1063.6% | -382.9% | -742.2% | -484.3% |
| Operating Margin | — | — | — | -2103.4% | -1277.8% | -1210.7% | -6717.2% | -1679.2% | -609.6% | -1190.7% | -729.6% |
| Net Profit Margin | — | — | — | -1858.0% | -1095.3% | -944.6% | -6469.1% | -1496.3% | -535.0% | -1183.5% | -465.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.4% | -63.4% | -88.1% | -180.6% | -112.5% | -63.6% | -168.9% | -55.3% | -40.2% | -29.1% | -13.3% |
| ROA | -37.9% | -37.9% | -45.2% | -88.1% | -83.0% | -48.0% | -109.0% | -39.3% | -29.8% | -22.1% | -10.2% |
| ROIC | -120.3% | -120.3% | -210.6% | -9934.7% | -634.5% | -1768.8% | -244.3% | -55.6% | -40.4% | -30.3% | -23.0% |
| ROCE | -75.9% | -75.9% | -125.0% | -186.4% | -121.5% | -78.2% | -143.7% | -52.4% | -40.2% | -26.7% | -18.9% |
BDRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $60892, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.09 | 0.10 | 0.20 | 0.07 | 0.04 | 0.31 | 0.07 | 0.19 | 0.05 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.11 | -1.18 | -0.70 | -0.89 | -1.08 | -0.25 | -0.06 | -0.19 | -0.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -120.77 | -120.77 | — | -181.56 | -159.15 | -137.77 | -689.29 | -111.61 | -20.12 | -117.99 | — |
Net cash position: cash ($9M) exceeds total debt ($60892)
BDRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Biodexa Pharmaceuticals Plc's current ratio of 2.03x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.26x to 2.03x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.03 | 2.03 | 1.75 | 1.26 | 2.47 | 6.39 | 3.10 | 2.42 | 2.27 | 2.22 | 2.39 |
| Quick Ratio | 2.03 | 2.03 | 1.75 | 1.39 | 2.47 | 6.39 | 3.10 | 2.42 | 2.27 | 2.11 | 2.30 |
| Cash Ratio | 1.39 | 1.39 | 0.33 | 1.07 | 1.49 | 5.46 | 2.52 | 1.93 | 0.95 | 1.58 | 1.88 |
| Asset Turnover | — | — | — | 0.04 | 0.13 | 0.04 | 0.03 | 0.02 | 0.09 | 0.02 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 8.85 | 9.46 |
| Days Sales Outstanding | — | — | — | 674.44 | 171.80 | 20.84 | 101.09 | 980.73 | 16.76 | 823.74 | 393.97 |
BDRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Biodexa Pharmaceuticals Plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $54861 | $61952 | $30 | $1 | $1 | $1 | $0 | $0 | $0 | $0 |
Peer Comparison
Compare BDRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BDRXYou | $1M | -0.1 | — | — | — | — | -63.4% | -120.3% | — |
 SIGA | $339M | 14.3 | 7.6 | 7.0 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 CORT | $5B | 62.3 | 114.9 | 38.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See BDRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDRX vs SIGA
Side-by-side business, growth, and profitability comparison vs SIGA Technologies, Inc..
Start ComparisonBDRX — Frequently Asked Questions
Quick answers to the most common questions about buying BDRX stock.
What is Biodexa Pharmaceuticals Plc's P/E ratio?
Biodexa Pharmaceuticals Plc's current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Biodexa Pharmaceuticals Plc's ROE?
Biodexa Pharmaceuticals Plc's return on equity (ROE) is -63.4%. The historical average is -73.2%.
Is BDRX stock overvalued?
Based on historical data, Biodexa Pharmaceuticals Plc is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.